A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
← catalyst calendarNCT07112339 · readout in 582 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
586estimated
Sites
75
Countries
Canada, Germany, Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-15 | actual | When the study began enrolling |
| Primary completion | 2028-03-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Interventions
- Drug: Insulin icodec
- Drug: Basal insulin analogues
Primary outcome
what the primary-completion date above is the date OFChange in glycated haemoglobin (HbA1c)
measured From baseline week 0 to week 52
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed